Loading...
GENI
XLON
Market cap5mUSD
Nov 20, Last price  
0.55GBP
1D
-8.33%
1Q
-37.14%
IPO
-98.57%
Name

Genincode PLC

Chart & performance

D1W1MN
XLON:GENI chart
P/E
—
P/S
1.35
EPS
—
Vol. 1Y
104.91%
Shs. 5Y
19.13%
Rev. 5Y
26.20%
Div Yld LY
—
Div Yld TTM
—
Revenues
3m
+13.88%
1,921,989960,8011,154,0001,430,0002,160,0002,701,0003,076,000
Net income
-6m
L+28.66%
-403,725-1,166,000-4,142,000-5,559,000-7,016,000-4,434,000-5,705,000
CFO
-4m
L-21.36%
-190,703-1,037,781-3,024,000-3,762,000-7,506,000-5,173,000-4,067,999

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.

Related entities

Subsidiaries
GEN INCODE S.L. (SOCIEDAD UNIPERSONAL)

Key people

William Rhodes
Independent Non-Executive Chairman of the Board · since 2021
Jordi Gilberte
Chief Operating Officer, Executive Director · since 2018
Matthew Walls
Chief Executive Officer, Executive Director · since 2018
Paul Foulger
Chief Financial Officer, Executive Director, Company Secretary · since 2023
Felix Frueh
Independent Non-Executive Director · since 2022
Huon Gray
Independent Non-Executive Director · since 2022
Sergio Olivero
Independent Non-Executive Director · since 2020
IPO date
Jul 22, 2021
Employees
34
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
ONE, ST. PETERS SQUARE
MANCHESTER, MAN M2 3DE
GB
Previous name
GENINCODE LIMITED
Previous name
GENINCODE UK LIMITED

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT